{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T11:23:40Z","timestamp":1767871420748,"version":"3.49.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","pathologyjournal.rcpa.edu.au","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.pathol.2017.02.004","type":"journal-article","created":{"date-parts":[[2017,5,6]],"date-time":"2017-05-06T04:30:27Z","timestamp":1494045027000},"page":"337-345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Role of plasma cells in Waldenstr\u00f6m macroglobulinaemia"],"prefix":"10.1016","volume":"49","author":[{"given":"Ali","family":"El-Ayoubi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James Q.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9703-6899","authenticated-orcid":false,"given":"Nadine","family":"Hein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipti","family":"Talaulikar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2017.02.004_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.02.004_bib2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/sonc.2003.50074","article-title":"Immunophenotypic analysis of Waldenstrom's macroglobulinemia","volume":"30","author":"San Miguel","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.pathol.2017.02.004_bib3","series-title":"WHO Classification of Tumours of Haemopoietic and Lymphoid Tissues","year":"2008"},{"key":"10.1016\/j.pathol.2017.02.004_bib4","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.3109\/10428194.2012.656103","article-title":"Waldenstrom macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005","volume":"53","author":"Sekhar","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pathol.2017.02.004_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.critrevonc.2008.03.008","article-title":"Lymphoplasmacytic lymphoma\u2013Waldenstrom's macroglobulinemia","volume":"67","author":"Vitolo","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.pathol.2017.02.004_bib6","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0889-8588(05)70130-1","article-title":"Waldenstr\u00f6m's macroglobulinemia","volume":"13","author":"Dimopoulos","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.pathol.2017.02.004_bib7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.pathol.2017.02.004_bib8","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1002\/cncr.26627","article-title":"Temporal and geographic variations of Waldenstrom macroglobulinemia incidence","volume":"118","author":"Wang","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2017.02.004_bib9","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1182\/blood-2016-04-711234","article-title":"Treatment recommendations from the Eighth International Workshop on Waldenstrom's Macroglobulinemia","volume":"128","author":"Leblond","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.02.004_bib10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/088506669501000304","article-title":"Hyperviscosity syndrome","volume":"10","author":"Gertz","year":"1995","journal-title":"J\u00a0Intensive Care Med"},{"key":"10.1016\/j.pathol.2017.02.004_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/CH-131691","article-title":"Hyperviscosity in plasma cell dyscrasias","volume":"55","author":"Kwaan","year":"2013","journal-title":"Clin Hemorheol Microcirc"},{"key":"10.1016\/j.pathol.2017.02.004_bib12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1188\/07.CJON.87-95","article-title":"Recognizing hyperviscosity syndrome in patients with Waldenstrom macroglobulinemia","volume":"11","author":"Mullen","year":"2007","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.pathol.2017.02.004_bib13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/ncpneuro0917","article-title":"Neurological manifestations of Waldenstr\u00f6m macroglobulinemia","volume":"4","author":"Baehring","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1016\/j.pathol.2017.02.004_bib14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3816\/CLM.2009.n.030","article-title":"Cold agglutinin\u2013mediated autoimmune hemolytic anemia in Waldenstr\u00f6m's macroglobulinemia","volume":"9","author":"Berentsen","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.pathol.2017.02.004_bib15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ajh.20207","article-title":"Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenstr\u00f6m macroglobulinemia does not indicate failure of response","volume":"77","author":"Ghobrial","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2017.02.004_bib16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cancergencyto.2006.04.009","article-title":"6q deletion discriminates Waldenstr\u00f6m macroglobulinemia from IgM monoclonal gammopathy of undetermined significance","volume":"169","author":"Schop","year":"2006","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.pathol.2017.02.004_bib17","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1309\/6U88-357U-UKJ5-YPT3","article-title":"Cytogenetic findings in lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinemia","volume":"116","author":"Mansoor","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.pathol.2017.02.004_bib18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3324\/haematol.2012.070458","article-title":"Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom's macroglobulinemia","volume":"98","author":"Nguyen-Khac","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2017.02.004_bib19","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/sj.leu.2404314","article-title":"Trisomy 4, a new chromosomal abnormality in Waldenstr\u00f6m's macroglobulinemia: a study of 39 cases","volume":"20","author":"Terre","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2017.02.004_bib20","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2017.02.004_bib21","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","article-title":"MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction","volume":"121","author":"Xu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.02.004_bib22","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.02.004_bib23","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V100.4.1505.h81602001505_1505_1507","article-title":"Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events","volume":"100","author":"Sahota","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.02.004_bib24","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/ni1201-1103","article-title":"Plasma cells: finding new light at the end of B cell development","volume":"2","author":"Calame","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.pathol.2017.02.004_bib25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/eji.1830160206","article-title":"Limiting dilution analysis of the B cell compartment in human bone marrow","volume":"16","author":"Hibi","year":"1986","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.pathol.2017.02.004_bib26","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/modpathol.2009.34","article-title":"Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenstrom's macroglobulinemia","volume":"22","author":"Morice","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2017.02.004_bib27","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/jcp.2010.088591","article-title":"Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia","volume":"64","author":"Pasricha","year":"2011","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.pathol.2017.02.004_bib28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.clml.2013.02.018","article-title":"Immunoglobulin M concentration in Waldenstrom macroglobulinemia: correlation with bone marrow B cells and plasma cells","volume":"13","author":"de Tute","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.pathol.2017.02.004_bib29","doi-asserted-by":"crossref","first-page":"824","DOI":"10.4065\/mcp.2010.0304","article-title":"Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines","volume":"85","author":"Ansell","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pathol.2017.02.004_bib30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3816\/CLML.2011.n.018","article-title":"Immunohistochemical phenotyping of plasma cells in lymphoplasmacytic lymphoma\/Waldenstrom's macroglobulinemia is comparable to flow cytometric techniques","volume":"11","author":"Howard","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.pathol.2017.02.004_bib31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1309\/3G1XDX0DVHBNVKB4","article-title":"Immunophenotypic profile of lymphoplasmacytic lymphoma\/Waldenstrom macroglobulinemia","volume":"124","author":"Konoplev","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.pathol.2017.02.004_bib32","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3816\/CLM.2005.n.008","article-title":"CD5, CD10, and CD23 expression in Waldenstr\u00f6m's macroglobulinemia","volume":"5","author":"Hunter","year":"2005","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.pathol.2017.02.004_bib33","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1182\/blood-2003-11-4024","article-title":"Clonotypic IgM V\/D\/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood","volume":"104","author":"Kriangkum","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.02.004_bib34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cyto.b.20512","article-title":"Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders","volume":"78","author":"Paiva","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.pathol.2017.02.004_bib35","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.beha.2010.09.002","article-title":"Immunophenotyping in multiple myeloma and related plasma cell disorders","volume":"23","author":"Kumar","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.pathol.2017.02.004_bib36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1309\/5EL22BH45PHUPM8P","article-title":"Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma","volume":"127","author":"Seegmiller","year":"2007","journal-title":"Am J Clin Pathology"},{"key":"10.1016\/j.pathol.2017.02.004_bib37","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1182\/blood-2006-11-055012","article-title":"Waldenstr\u00f6m macroglobulinemia","volume":"109","author":"Vijay","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.02.004_bib38","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3816\/CLM.2005.n.016","article-title":"CD52 Expression in Waldenstr\u00f6m's macroglobulinemia: implications for alemtuzumab therapy and response assessment","volume":"5","author":"Owen","year":"2005","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.pathol.2017.02.004_bib39","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2009-05-174359","article-title":"How I treat Waldenstrom macroglobulinemia","volume":"114","author":"Treon","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.02.004_bib40","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1182\/blood-2012-09-457101","article-title":"Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstr\u00f6m's macroglobulinemia and related lymphoid neoplasms","volume":"121","author":"Varettoni","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.02.004_bib41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2017.02.004_bib42","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri1391","article-title":"Toll-like receptor signalling","volume":"4","author":"Akira","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pathol.2017.02.004_bib43","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2007-09-115170","article-title":"Targeting NF-\u03baB in Waldenstrom macroglobulinemia","volume":"111","author":"Leleu","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.02.004_bib44","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1182\/blood-2015-11-684183","article-title":"B\u00a0cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B cell lymphoma in mice","volume":"127","author":"Knittel","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.02.004_bib45","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1084\/jem.20131424","article-title":"Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance","volume":"211","author":"Wang","year":"2014","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.pathol.2017.02.004_bib46","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.molmed.2010.01.003","article-title":"Chemokines and chemokine receptors: new insights into cancer-related inflammation","volume":"16","author":"Lazennec","year":"2010","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.pathol.2017.02.004_bib47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/84219","article-title":"Lymphocyte traffic control by chemokines","volume":"2","author":"Moser","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.pathol.2017.02.004_bib48","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2005-08-3182","article-title":"CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment","volume":"107","author":"Burger","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.02.004_bib49","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc1388","article-title":"Cancer and the chemokine network","volume":"4","author":"Balkwill","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pathol.2017.02.004_bib50","doi-asserted-by":"crossref","first-page":"C987","DOI":"10.1152\/ajpcell.00406.2006","article-title":"Stroma-derived factor (SDF-1\/CXCL12) and human tumor pathogenesis","volume":"292","author":"Kryczek","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.pathol.2017.02.004_bib51","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1182\/blood-2007-12-129395","article-title":"SDF-1\/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia","volume":"112","author":"Ngo","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.02.004_bib52","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1158\/1078-0432.CCR-15-0646","article-title":"Genomic landscape of CXCR4 mutations in Waldenstrom macroglobulinemia","volume":"22","author":"Poulain","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2017.02.004_bib53","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11864-016-0391-7","article-title":"Waldenstrom Macroglobulinemia: familial predisposition and the role of genomics in prognosis and treatment selection","volume":"17","author":"Kapoor","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.pathol.2017.02.004_bib54","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/leu.2014.187","article-title":"The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia","volume":"29","author":"Cao","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2017.02.004_bib55","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2016-03-708263","article-title":"Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenstr\u00f6m macroglobulinemia","volume":"128","author":"Hunter","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.02.004_bib56","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.clml.2016.04.014","article-title":"Clinical validation of a CXCR4 mutation screening assay for Waldenstrom macroglobulinemia","volume":"16","author":"Ballester","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.pathol.2017.02.004_bib57","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/bjh.13897","article-title":"Clonal architecture of CXCR4 WHIM-like mutations in Waldenstr\u00f6m macroglobulinaemia","volume":"172","author":"Xu","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pathol.2017.02.004_bib58","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1073\/pnas.88.8.3436","article-title":"Tyrosine phosphorylation of components of the B-cell antigen receptors following receptor crosslinking","volume":"88","author":"Gold","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pathol.2017.02.004_bib59","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.iy.10.040192.000525","article-title":"Antigen receptors on B lymphocytes","volume":"10","author":"Reth","year":"1992","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.pathol.2017.02.004_bib60","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/343760a0","article-title":"Molecular components of the B-cell antigen receptor complex of the IgM class","volume":"343","author":"Hombach","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2017.02.004_bib61","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/338383b0","article-title":"Antigen receptor tail clue","volume":"338","author":"Reth","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2017.02.004_bib62","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/0960-9822(93)90062-S","article-title":"B-cell antigen receptor motifs have redundant signalling capabilities and bind the tyrosine kinases PTK72, Lyn and Fyn","volume":"3","author":"Law","year":"1993","journal-title":"Curr Biol"},{"key":"10.1016\/j.pathol.2017.02.004_bib63","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1084\/jem.178.3.1049","article-title":"Signal transduction by immunoglobulin is mediated through Ig alpha and Ig beta","volume":"178","author":"Sanchez","year":"1993","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.pathol.2017.02.004_bib64","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1146\/annurev.immunol.17.1.555","article-title":"Genetic analysis of B cell antigen receptor signaling","volume":"17","author":"Kurosaki","year":"1999","journal-title":"Ann Rev Immunol"},{"key":"10.1016\/j.pathol.2017.02.004_bib65","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1084\/jem.20060221","article-title":"Ig beta tyrosine residues contribute to the control of B cell receptor signaling by regulating receptor internalization","volume":"203","author":"Gazumyan","year":"2006","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.pathol.2017.02.004_bib66","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2017.02.004_bib67","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1182\/blood-2014-09-602565","article-title":"The cellular origin and malignant transformation of Waldenstrom macroglobulinemia","volume":"125","author":"Paiva","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.02.004_bib68","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1074-7613(00)80511-7","article-title":"Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation","volume":"7","author":"Chan","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.pathol.2017.02.004_bib69","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1002\/eji.200737293","article-title":"MyD88-dependent autoimmune disease in Lyn-deficient mice","volume":"37","author":"Silver","year":"2007","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.pathol.2017.02.004_bib70","doi-asserted-by":"crossref","first-page":"875","DOI":"10.4049\/jimmunol.1300683","article-title":"Requirement for MyD88 signaling in B cells and dendritic cells for germinal center anti-nuclear antibody production in Lyn-deficient mice","volume":"192","author":"Hua","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.pathol.2017.02.004_bib71","doi-asserted-by":"crossref","first-page":"792","DOI":"10.2353\/ajpath.2010.091286","article-title":"Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma","volume":"177","author":"Tripodo","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pathol.2017.02.004_bib72","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3324\/haematol.10755","article-title":"Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenstrom's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance","volume":"92","author":"Martin-Jimenez","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2017.02.004_bib73","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/leu.2012.257","article-title":"IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstrom macroglobulinemia\/lymphoplasmacytic lymphomas","volume":"27","author":"Gachard","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2017.02.004_bib74","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.3109\/10428194.2013.779689","article-title":"Clues to pathogenesis of Waldenstrom macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors","volume":"54","author":"Varettoni","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pathol.2017.02.004_bib75","doi-asserted-by":"crossref","first-page":"809103","DOI":"10.1155\/2014\/809103","article-title":"Clonotypic analysis of immunoglobulin heavy chain sequences in patients with Waldenstrom's macroglobulinemia: correlation with MYD88 L265P somatic mutation status, clinical features, and outcome","volume":"2014","author":"Petrikkos","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.pathol.2017.02.004_bib76","doi-asserted-by":"crossref","first-page":"13447","DOI":"10.1073\/pnas.1514944112","article-title":"Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens","volume":"112","author":"Young","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pathol.2017.02.004_bib77","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3816\/CLM.2009.n.030","article-title":"Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenstrom's macroglobulinemia","volume":"9","author":"Berentsen","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.pathol.2017.02.004_bib78","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3324\/haematol.2013.091702","article-title":"Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma","volume":"99","author":"Randen","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2017.02.004_bib79","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2006-02-005488","article-title":"Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma","volume":"108","author":"Chng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.02.004_bib80","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1182\/blood-2011-04-351742","article-title":"Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity","volume":"118","author":"Elsawa","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.02.004_bib81","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/sj.leu.2404520","article-title":"Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals","volume":"21","author":"Gutierrez","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2017.02.004_bib82","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.clml.2013.02.015","article-title":"Genomic abnormalities of Waldenstr\u00f6m macroglobulinemia and related low-grade B-cell lymphomas","volume":"13","author":"Braggio","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.pathol.2017.02.004_bib83","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/modpathol.2011.213","article-title":"Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities","volume":"25","author":"Braggio","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2017.02.004_bib84","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-\u03ba B in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2017.02.004_bib85","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood-2008-12-194852","article-title":"TNFAIP3\/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas","volume":"114","author":"Honma","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2017.02.004_bib86","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nature07969","article-title":"Frequent inactivation of A20 in B-cell lymphomas","volume":"459","author":"Kato","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2017.02.004_bib87","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1084\/jem.20090528","article-title":"TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma","volume":"206","author":"Schmitz","year":"2009","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.pathol.2017.02.004_bib88","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pathol.2017.02.004_bib89","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3324\/haematol.2012.068478","article-title":"Molecular pathogenesis of Waldenstr\u00f6m's macroglobulinemia","volume":"97","author":"Braggio","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2017.02.004_bib90","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1158\/0008-5472.CAN-08-3701","article-title":"Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-\u03baB signaling pathways in Waldenstr\u00f6m's macroglobulinemia","volume":"69","author":"Braggio","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.pathol.2017.02.004_bib91","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2017.02.004_bib92","first-page":"438","article-title":"Primary treatment of Waldenstrom's macroglobulinemia with dexamethasone, rituximab and cyclophosphamide (DRC): final analysis of a phase II study","volume":"120","author":"Dimopoulos","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.pathol.2017.02.004_bib93","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2017.02.004_bib94","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.3109\/10428194.2010.524326","article-title":"Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenstrom macroglobulinemia","volume":"51","author":"Peinert","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pathol.2017.02.004_bib95","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/cncr.26303","article-title":"Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease","volume":"118","author":"Tedeschi","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2017.02.004_bib96","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.clml.2013.02.011","article-title":"Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenstrom's macroglobulinemia","volume":"13","author":"Tedeschi","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.pathol.2017.02.004_bib97","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/039463200601900218","article-title":"Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome","volume":"19","author":"Goteri","year":"2006","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.pathol.2017.02.004_bib98","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3816\/CLM.2009.n.013","article-title":"Assessment of bone marrow response in Waldenstrom's macroglobulinemia","volume":"9","author":"Varghese","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.pathol.2017.02.004_bib99","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1309\/AJCP15YFULCZHZVH","article-title":"Residual monotypic plasma cells in patients with waldenstrom macroglobulinemia after therapy","volume":"135","author":"Barakat","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.pathol.2017.02.004_bib100","first-page":"FD12","article-title":"Persistent monotypic plasma cells with absence of neoplastic B cell component in a treated case of waldenstrom macroglobulinemia: a sign of residual disease?","volume":"8","author":"Gajendra","year":"2014","journal-title":"J\u00a0Clin Diagn Res"},{"key":"10.1016\/j.pathol.2017.02.004_bib101","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/bjh.13996","article-title":"To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenstr\u00f6m macroglobulinaemia","volume":"176","author":"Gustine","year":"2016","journal-title":"Br J Haematol"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302517300041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302517300041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T23:43:43Z","timestamp":1719186223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302517300041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0031302517300041"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2017.02.004","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of plasma cells in Waldenstr\u00f6m macroglobulinaemia","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2017.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}